A Three-Gene Signature for Predicting the Prognosis of Patients Treated with Transarterial Chemoembolization (TACE) and Identification of PD-184352 as a Potential Drug to Reverse Nonresponse to TACE

<div>Eight genes related to the probability of overall survival (OS) in GSE14520 and their interactions and correlation relationships. (a) The forest map in the table shows that 8 of the 17 genes were related to poor OS in patients treated with TACE. HR: hazard ratio; CI: confidence interval. (b) A PPI of these eight molecules was plotted using Cytoscape. (c) The correlation heat map of these genes in the TACE nonresponse group of GSE104580.</div>

Journal of Oncology

fig2

Figure 2

Figure 2: A Three-Gene Signature for Predicting the Prognosis of Patients Treated with Transarterial Chemoembolization (TACE) and Identification of PD-184352 as a Potential Drug to Reverse Nonresponse to TACE 

Figure 2 | A Three-Gene Signature for Predicting the Prognosis of Patients Treated with Transarterial Chemoembolization (TACE) and Identification of PD-184352 as a Potential Drug to Reverse Nonresponse to TACE 